CAMBRIDGE, Mass.--(BUSINESS WIRE)--NinePoint Medical, Inc., an emerging leader in the development of medical devices for in vivo pathology, today announced that data from a Massachusetts General Hospital (MGH) study using next-generation optical frequency domain imaging (OFDI) technology in patients was presented at The 19th United European Gastroenterology Week (UEGW 2011) in Stockholm. In the study, OFDI technology with laser marking was utilized for the first time to conduct guided biopsies of the distal esophagi in seven patients. The authors conducting the study concluded that with its endomicroscopic imaging and laser marking capabilities, OFDI-guided biopsy may potentially enable more targeted biopsies and change the current treatment paradigm for precancerous areas in the esophagus. The OFDI technology was licensed to NinePoint Medical in 2010.
